CCCC - CIK 0001662579
C4 Therapeutics, Inc. (CCCC) reported revenue of $35.95M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $35.95M | +1.0% |
| FY 2024 | $35.58M | +71.4% |
| FY 2023 | $20.76M | -33.3% |
| FY 2022 | $31.10M | -32.1% |
| FY 2021 | $45.78M | - |
C4 Therapeutics, Inc. (CCCC) reported revenue of $35.95M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2021 and fiscal 2025, C4 Therapeutics, Inc.'s revenue declined from $45.78M to $35.95M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.